Nova Mentis Receives Institutional Review Board Approval to Commence Psilocybin Clinical Trial

Stock Information for Restart Life Sci

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Restart Life Sci

Restart Life Introduces BrainQ(TM) - A Wholly Owned Brand
Restart Life Introduces BrainBalls(TM) Product Line
Nova Mentis Assigns Intellectual Property
Nova Mentis Announces Change of Directors
Nova Mentis Applauds Government Decision to Create Rare Disease Advisory Group
Nova Mentis Announces Participant Screening Underway in Canada's First Psilocybin Clinical Trial for Fragile X Syndrome
Nova Mentis to Enter mRNA AI Diagnostics Business
Nova Mentis Begins Recruitment in First-of-its-Kind Health Canada Psilocybin Trial

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.